MUHC research news
New research published in the online version of the Annals of Internal Medicine today documents an increased risk of heart attack with one of the COX-2 inhibitors used in elderly adults with no previous history of heart attack.
For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects.
The discoveries of two investigators from the Research Institute of the McGill University Health Centre (MUHC) have been listed in the prestigious Québec Science magazine's Top Ten Discoveries of 2004.
A first-ever study of how evolving diagnostic and therapy guidelines in conjunction with community programs affect breast cancer population mortality found a possible link between death rates and the way cancer care is organized.
Independent research teams based at Northwestern University in the U.S. and at the McGill University Health Centre (MUHC) in Canada are reporting similar findings about a rare and potentially life-threatening form of anemia known as antibody-associated pure red-cell aplasia (PRCA).
McGill University Health Centre (MUHC) researcher Dr. Antonio Vigano has published a new study looking at the relationship between survival and quality of life in patients with terminal cancer.
Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial.
New research findings from the Research Institute of the McGill University Health Center (MUHC) provide hope for patients with multiple sclerosis (MS), one of the most common and devastating diseases of the nervous system.